2-(pent-4-ynyl)-2-oxazoline | 891770-59-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 2-(pent-4-ynyl)-2-oxazoline
• 英文别名: 2-(4-Pentynyl)-2-oxazoline；2-pent-4-ynyl-4,5-dihydro-1,3-oxazole
• CAS: 891770-59-5
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: MNUUNDKDTPELEI-UHFFFAOYSA-N

物化性质

• 密度：
  1.005 g/mL at 25 °C
• 闪点：
  91℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-己炔酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 131.0h， 生成 2-(pent-4-ynyl)-2-oxazoline
  参考文献：
  名称：

  用于合成纳米颗粒的多功能嵌段共聚（2-恶唑啉）模块化工具包

  摘要：

  聚合后改性提供了一种将化学官能团引入大分子以生产具有优异性能的定制材料的优雅方式。这一概念适用于定义明确的聚（2-恶唑啉）系列嵌段共聚物，并证明了这些大分子作为众多应用的通用工具包的巨大潜力。合成了具有分离的水溶性、炔烃和烯烃链段的三嵌段共聚物，并通过铜（I）催化的叠氮化物 - 炔烃环加成（CuAAC）和硫醇 - 烯（TE）点击用各种低分子量功能分子正交改性反应，分别。代表性的工具包聚合物用于合成金、氧化铁和二氧化硅纳米粒子。

  DOI：

  10.1002/chem.202101327

文献信息

• [EN] POLYOXAZOLINE ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT DE POLYOXAZOLINE
  申请人：SERINA THERAPEUTICS INC

  公开号：WO2016019340A1

  公开（公告）日：2016-02-04

  In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.

  本公开描述了聚合物偶联物，包括聚合物-抗体-药物偶联物（聚合物ADCs），以及使用这些偶联物治疗人类疾病。该聚合物偶联物可以含有大量的聚合物结合剂，从而有效提高抗体的药物抗体比率（DAR），显著超过目前现有技术。当使用针对低密度抗原的抗体作为靶点抗体时，这一点可能尤为重要。与传统的ADC相比，所述聚合物ADC具有改善的药代动力学和溶解性。毒素与聚合物之间的连接器可以根据需要在肿瘤内特定部位和特定条件下释放毒素进行定制。当前公开的聚合物ADC的另一个特点是，可以在聚合物主链上附着一个纯化部分，以提供聚合物ADC的纯化便利。
• Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same
  申请人：SERINA THERAPEUTICS, INC.

  公开号：US20150273074A1

  公开（公告）日：2015-10-01

  The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers find for conjugating to molecules such as targeting, diagnostic and therapeutic agents.

  本公开提供了具有两个或三个反应性功能基团的2-取代-2-噁唑烯共聚物，这些功能基团在化学上也是正交的。所述的共聚物可以是随机共聚物、嵌段共聚物或随机和嵌段共聚物配置的混合物。此外，本公开提供了合成上述聚合物的新方法，用于与靶向、诊断和治疗剂等分子结合。
• Polyoxazolines with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds
  申请人：Bentley Michael David

  公开号：US20110123453A1

  公开（公告）日：2011-05-26

  The present disclosure provides novel functional polyoxazoline derivatives prepared by terminating polyoxazoline polymerization with inert chemical groups. In addition, the present disclosure demonstrates the synthesis of novel electrophilic initiators with protected functional groups capable of initiating oxazoline polymerization and capable of surviving the conditions of polymerization. These initiators are used to synthesize the above inert-terminal polyoxazoline derivatives as well as other poly-oxazolines with active terminal groups. Furthermore, the present disclosure provides for polyoxazoline-lipid conjugates and liposomal compositions prepared using such polyoxazoline-lipid conjugates. Methods of using the foregoing to prepare conjugates with target molecules are also disclosed.

  本公开提供了通过使用惰性化学基团终止聚合反应制备的新型功能性聚氧氮杂环衍生物。此外，本公开还展示了合成具有受保护功能基团的新型亲电引发剂的方法，这些引发剂能够引发氧氮杂环聚合反应并能够在聚合反应条件下存活。这些引发剂用于合成上述惰性末端聚氧氮杂环衍生物以及其他具有活性末端基团的聚氧氮杂环。此外，本公开还提供了聚氧氮杂环-脂质共轭物和使用这种聚氧氮杂环-脂质共轭物制备的脂质体组合物。还公开了使用上述方法制备与目标分子结合物的方法。
• Polyoxazoline Antibody Drug Conjugates
  申请人：Serina Therapeutics, Inc.

  公开号：US20160030592A1

  公开（公告）日：2016-02-04

  In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.

  本公开说明书描述了高分子共轭物，包括高分子-抗体-药物共轭物（高分子ADC），以及使用这些共轭物治疗人类疾病。高分子共轭物可以包含大量高分子结合的药物，从而有效地将抗体的药物比例（DAR）显著提高到目前可用技术之外。当用于低密度抗原的抗体时，这可能特别重要。所述的高分子ADC相对于传统ADC具有改进的药代动力学和溶解度。代理和高分子之间的连接剂可以定制以在肿瘤内所需的位置和条件下释放毒素。本公开说明书的高分子ADC的另一个特点是可以将净化基团附加到高分子骨架上，以提供高分子ADC的易于纯化性。
• Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
  申请人：Serina Therapeutics, Inc.

  公开号：EP2669313A1

  公开（公告）日：2013-12-04

  The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.

  本公开提供了具有两个或三个活性官能团且化学性质正交的 2-取代-2-噁唑啉共聚物。所述共聚物可以是无规共聚物、嵌段共聚物或无规共聚物和嵌段共聚物的混合物。此外，本公开还提供了合成上述聚合物以及与靶向、诊断和治疗剂等分子共轭的新方法。